CD16 and interleukin 2 expressing natural killer cells - NantKwest

Drug Profile

CD16 and interleukin 2 expressing natural killer cells - NantKwest

Alternative Names: haNK; High affinity natural killer cells - NantKwest; NK-92 [CD16.158V, ER IL-2]

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NantKwest
  • Class Antineoplastics; Cell adhesion molecules; Cell therapies; Gene therapies; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer; Colorectal cancer; Pancreatic cancer; Squamous cell cancer
  • Phase I Solid tumours
  • Preclinical Head and neck cancer

Most Recent Events

  • 02 Jul 2018 NantKwest plans the QUILT-2.024 phase II trial for Non Small Cell Lung Cancer (Late-stage disease) in USA , (NCT03574649)
  • 28 Jun 2018 NantKwest plans a phase I/II trial for Hepatocellular carcinoma (Late-stage disease, Inoperable/Unresectable, Recurrent) in USA in June 2018 (NCT03563170)
  • 20 Jun 2018 NantKwest plans the QUILT-3.088 phase II trial for Pancreatic Cancer (Metastatic disease) in USA , (NCT03563144)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top